Aspects of prophylactic treatment of hemophilia
(2016) In Thrombosis Journal 14(S.1).- Abstract
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in... (More)
Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.
(Less)
- author
- Ljung, Rolf LU
- organization
- publishing date
- 2016-10-04
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Factor IX, Factor VIII, Hemophilia A, Hemophilia B, Prophylaxis
- in
- Thrombosis Journal
- volume
- 14
- issue
- S.1
- article number
- 30
- publisher
- BioMed Central (BMC)
- external identifiers
-
- pmid:27766056
- wos:000395268200014
- scopus:84990041946
- ISSN
- 1477-9560
- DOI
- 10.1186/s12959-016-0103-3
- language
- English
- LU publication?
- yes
- id
- 0bd6f211-18cf-4bc6-9618-257e115bf42a
- date added to LUP
- 2016-10-21 07:55:42
- date last changed
- 2024-10-05 03:56:25
@article{0bd6f211-18cf-4bc6-9618-257e115bf42a, abstract = {{<p>Retrospective and prospective studies unambiguously show that prophylactic treatment of severe hemophilia A or B should be started as primary prophylaxis at 1-2 years' of age and ideally before the first joint bleed. The dose and dose frequency should be individually tailored depending on the goal of treatment, venous access and the bleeding phenotype. The circumstances during the first exposures of factor VIII concentrates in hemophilia A may have an impact on the risk of developing inhibitors. Enhanced half-life products, in particular in hemophilia B, will facilitate treatment in patients with difficult venous access but also in achieving a higher trough level. Evidence accumulate that prophylactic treatment is beneficial also in adults and in patients with inhibitors.</p>}}, author = {{Ljung, Rolf}}, issn = {{1477-9560}}, keywords = {{Factor IX; Factor VIII; Hemophilia A; Hemophilia B; Prophylaxis}}, language = {{eng}}, month = {{10}}, number = {{S.1}}, publisher = {{BioMed Central (BMC)}}, series = {{Thrombosis Journal}}, title = {{Aspects of prophylactic treatment of hemophilia}}, url = {{http://dx.doi.org/10.1186/s12959-016-0103-3}}, doi = {{10.1186/s12959-016-0103-3}}, volume = {{14}}, year = {{2016}}, }